Combination antifungals: An update

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 5, 2007, Pages 883-892

  Segal, Brahm H ^a   Steinbach, William J ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Candida; Combination antifungal; Cryptococcus; Review

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CAY 1; CECROPIN A; CYCLOSPORIN A; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; GM 237354; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SORDARIN; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TOXICITY; CANDIDA; CANDIDEMIA; CELLULAR STRESS SIGNAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; ENDOCARDITIS; EYE DISEASE; GASTROINTESTINAL TOXICITY; GENE SEQUENCE; GENOMICS; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; MENINGITIS; MONOTHERAPY; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; REVIEW;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; CRYPTOCOCCUS NEOFORMANS; DRUG THERAPY, COMBINATION; FUNGEMIA; HUMANS; MENINGITIS, CRYPTOCOCCAL; RANDOMIZED CONTROLLED TRIALS; SIGNAL TRANSDUCTION;

EID: 35349019258     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.5.883     Document Type: Review

References (79)

1. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33(5), 641-647 (2001).
2. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis. 29(2), 239-244 (1999).
3. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33(2), 177-186 (2001).
4. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J. Antimicrob. Chemother. 41(Suppl. D), 1-5 (1998).
5. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med. 173(7), 707-717 (2006).
6. Utz JP, Garriques IL, Sande MA et al. Therapy of cryptococcosis with a combination of flucytosine and amphotericin B. J. Infect. Dis. 132(4), 368-373 (1975).
7. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 301 (3), 126-131 (1979).
8. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 113(3), 183-187 (1990).
9. van der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337(1), 15-21 (1997).
10. Brouwer AE, Rajanuwong A, Chierakul W et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 363(9423), 1764-1767 (2004).
11. Barchiesi F, Schimizzi AM, Caselli F et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44(9), 2435-2441 (2000).
12. Nguyen MH, Najvar LK, Yu CY, Graybill JR. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob. Agents Chemother. 41(5), 1120-1123 (1997).
13. Barchiesi F, Schimizzi AM, Najvar LK et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45(5), 1355-1359 (2001).
14. Mayanja-Kizza H, Oishi K, Mitarai S et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin. Infect. Dis. 26(6), 1362-1366 (1998).
15. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000).
16. Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51(1), 383-385 (2007).
17. Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 50(1), 113-120 (2006).
18. Te Dorsthorst DT, Verweij PE, Meletiadis J et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46(9), 2982-2989 (2002).
19. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42(6), 1382-1386 (1998).
20. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob. Agents Chemother. 45(2), 485-494 (2001).
21. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39(3), 598-601 (1995).
22. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36(10), 1221-1228 (2003).
23. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
24. Betts RF, Rotstein C, Talwar D et al. Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (IC). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, September 17-20, 2006 (Abstract M-1308a).
25. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356(24), 2472-2482 (2007).
26. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 369(9572), 1519-1527 (2007).
27. Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis. Antimicrob. Agents Chemother. 47(7), 2373-2375 (2003).
28. Hauser M, Hess J, Belohradsky BH. Treatment of Candida albicans endocarditis: case report and a review. Infection 31(2), 125-127 (2003).
29. Bisbe J, Miro JM, Latorre X et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin. Infect. Dis. 15(6), 910-923 (1992).
30. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002).
31. Odds FC, Van Gerven F, Espinel-Ingroff A et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42(2), 282-288 (1998).
32. Te Dorsthorst DTA, Mouton JW, van den Beukel CJP, van der Lee HAL, Meis JFGM, Verweij PE. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates. Antimicrob. Agents Chemother. 48, 3147-3150 (2004).
33. Warn PA, Sharp A, Guinea J, Denning DW. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole, and micafungin against Aspergillus and Candida. J. Antimicrob. Chemother. 53, 743-749 (2004).
34. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis. 37(Suppl. 3), S188-S224 (2003).
35. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 46(10), 3208-3214 (2002).
36. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob. Agents Chemother. 44(10), 2915-2918 (2000).
37. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36(11-12), 421-424 (1993).
38. Meletiadis J, te Dorsthorst DT, Verweij PE. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int. J. Antimicrob. Agents 28(5), 439-449 (2006).
39. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47(2), 331-385 (1995).
40. Hope WW, Warn PA, Sharp A et al. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J. Infect. Dis. 192(4), 673-680 (2005).
41. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob. Agents Chemother. 51(6), 2053-2064 (2007).
42. Brun YF, Dennis CG, Greco WR et al. Modeling the combination of amphotericin b, micafungin, and nikkomycin Z against Aspergillus fumigatus in vitro using a novel response surface paradigm. Antimicrob. Agents Chemother. 51(5), 1804-1812 (2007).
43. White DB, Faessel HM, Slocum HK, Khinkis L, Greco WR. Non-linear response surfaces and mixture experiment methodologies applied to the study of synergism. Biom. J. 46, 56-71 (2004).
44. White DB, Slocum HK, Brun Y, Wrzosek C, Greco WR. A new nonlinear mixture response surface paradigm for the study of synergism: a three drug example. Curr. Drug Metab. 4, 399-409 (2003).
45. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52(1), 1 (2003).
46. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G et al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49(3), 1232-1235 (2005).
47. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 46(9) 3039-3041 (2002).
48. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. 45 (12), 3310-3321 (2001).
49. Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob. Agents Chemother. 44, 2547-2548 (2000).
50. Ganesan LT, Manavathu EK, Cutright JL, Alangaden GJ, Chandrasekar PH. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin. Microbiol. Infect. 10(11), 961-966 (2004).
51. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46(8), 2564-2568 (2002).
52. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187(12), 1834-1843 (2003).
53. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. 47, 1452-1455 (2003).
54. -/- mouse model of chronic granulomatous disease. Antimicrob. Agents Chemother. 50(2), 422-427 (2006).
55. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive aspergillosis. Clin. Microbiol. Infect. 10, 925-928 (2004).
56. Sivak O, Bartlett K, Risovic V et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J. Pharm. Sci. 93, 1382-1389 (2004).
57. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. 52, 656-662 (2003).
58. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 97(4), 1025-1032 (2003).
59. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98(2), 292-299 (2003).
60. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39(6), 797-802 (2004).
61. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12), 2888-2897 (2006).
62. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 39(11), 1563-1571 (2004).
63. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53(5), 337-349 (2006).
64. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, DePauw BE, Walsh TJ, Segal BH. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin. Infect. Dis. 43(11), 1449-1455 (2006).
65. Kraus PR, Heitman J. Coping with stress: calmodulin and calcineurin in model and pathogenic fungi. Biochem. Biophys. Res. Commun. 311(4), 1151-1157 (2003).
66. Blankenship JR, Wormley FL, Boyce MK et al. Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryotic Cell 2(3), 422-430 (2003).
67. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16(10), 2576-2589 (1997).
68. Cruz MC, Fox DS, Heitman J. Calcineurin is required for hyphal elongation during mating and haploid fruiting in Cryptococcus neoformans. EMBO J. 20(5), 1020-1032 (2001).
69. Steinbach WJ, Schell WA, Blankenship JR, Onyewu C, Heitman J, Perfect JR. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob. Agents Chemother. 48(5), 1664-1669 (2004).
70. Steinbach WJ, Reedy JL, Cramer RA Jr, Perfect JR, Heitman J. Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat. Rev. Microbiol. 5(6), 418-430 (2007).
71. Steinbach WJ, Cramer RA Jr, Perfect BZ et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob. Agents Chemother. 51(8), 2979-2981 (2007).
72. Segal BH, Wang XY, Dennis CG et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today 11(11-12), 534-540 (2006).
73. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309(5744), 2185-2189 (2005).
74. Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47(7), 2208-2216 (2003).
75. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42(10), 1404-1413 (2006).
76. Segal BH, Kwon-Chung J, Walsh TJ et al. Immunotherapy for fungal infections. Clin. Infect. Dis. 42(4), 507-515 (2006).
77. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356(4), 348-359 (2007).
78. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356(4), 335-347 (2007).
79. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin. Infect. Dis. 44(3), 402-409 (2007).